We are live on ! Find out more
AEGR

Aegerion Pharmaceuticals
AEGR

Delisted

AEGR was delisted on the 29th of November, 2016.

Back to rankings

145 hedge funds and large institutions have $1.94B invested in Aegerion Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 145 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more call options, than puts

Call options by funds: $122M | Put options by funds: $90.3M

Holders
145
Holders Change
+145
Holders Change %
–
% of All Funds
4.73%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.13%
New
145
Increased
–
Reduced
–
Closed
–
Calls
$122M
Puts
$90.3M
Net Calls
+$31.3M
Net Calls Change
+$31.3M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RIM
26
RS Investment Management
California
$16.5M +$13.8M +260,726 New
MHP
27
Manatuck Hill Partners
Connecticut
$15.7M +$13.1M +247,400 New
ZDA
28
Zweig-DiMenna Associates
New York
$13.7M +$11.5M +216,690 New
Federated Hermes
29
Federated Hermes
Pennsylvania
$13.7M +$11.5M +216,500 New
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$13.5M +$11.3M +213,566 New
Wellington Management Group
31
Wellington Management Group
Massachusetts
$13.2M +$11.1M +208,756 New
Morgan Stanley
32
Morgan Stanley
New York
$12.8M +$10.7M +201,486 New
SCA
33
Southpoint Capital Advisors
New York
$12.7M +$10.6M +200,000 New
RIM
34
Rainier Investment Management
Washington
$12.4M +$10.4M +196,180 New
TCIM
35
TIAA CREF Investment Management
New York
$11.5M +$9.62M +181,264 New
CA
36
Commerzbank Aktiengesellschaft
Germany
$11.4M +$9.57M +180,259 New
EA
37
Emerald Advisers
Pennsylvania
$11M +$9.21M +173,386 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$9.13M +$7.66M +144,185 New
DCM
39
Driehaus Capital Management
Illinois
$8.92M +$7.48M +140,837 New
HM
40
HealthCor Management
New York
$8.03M +$6.73M +126,700 New
FAM
41
Fred Alger Management
New York
$6.96M +$5.84M +109,967 New
Wells Fargo
42
Wells Fargo
California
$6.6M +$5.53M +104,223 New
HCM
43
Highbridge Capital Management
New York
$6.44M +$5.4M +101,688 New
TA
44
Teachers Advisors
New York
$6.16M +$5.16M +97,267 New
CIP
45
Chartwell Investment Partners
Pennsylvania
$5.98M +$5.01M +94,411 New
ARTA
46
A.R.T. Advisors
New York
$5.78M +$4.84M +91,216 New
Barclays
47
Barclays
United Kingdom
$5.33M +$4.47M +84,124 New
Geode Capital Management
48
Geode Capital Management
Massachusetts
$4.86M +$4.07M +76,703 New
BIM
49
BlackRock Investment Management
Delaware
$4.84M +$4.06M +76,411 New
GIM
50
Granahan Investment Management
Massachusetts
$4.77M +$4M +75,350 New
1
2
3 4 5

AEGR Hedge Fund Activity: Q2 2013 in Review

145 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q2 2013, worth a combined $1.94B.

Buyers outnumbered sellers: 145 funds opened new AEGR positions and 0 closed out — a net gain of 145 holders — while 0 added to existing stakes and 0 trimmed.

  • 145 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $1.94B of Aegerion Pharmaceuticals stock for Q2 2013.
  • 145 funds opened new Aegerion Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +145 holders.

Based on aggregated 13F filings for Q2 2013.